Loading clinical trials...
Loading clinical trials...
A Phase I Study of Inotuzumab Ozogamicin (CMC-544) in Combination With Temsirolimus (CCI-779) in Patients With Relapsed or Refractory CD22-positive B-cell Non Hodgkin's Lymphomas
Conditions
Interventions
Inotuzumab Ozogamicin
Temsirolimus
Locations
3
Switzerland
InselSpital, Universitätsspital Bern
Bern, Canton of Bern, Switzerland
Oncology Institute of Southern Switzerland
Bellinzona, Canton Ticino, Switzerland
Kantonsspital St.Gallen
San Gallen, San Gallen, Switzerland
Start Date
December 1, 2011
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
June 7, 2016
NCT06552559
NCT04531046
NCT04214886
NCT05318963
NCT05130489
NCT03367143
Lead Sponsor
Cristiana Sessa
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions